Condition: Oncology · NSCLC Stage IV · NSCLC, Stage III · Sponsor: Vestre Viken Hospital Trust
A Randomized, Multicenter Study Investigating Efficacy and Safety of anti-PD-1/PD-L1-treatment +/- UV1 vaccination as first line treatment in patients with inoperable advanced or metastatic non-small cell lung cancer. The objective of the phase 2 study is to induce a meaningful Progression-Free Survival (PFS) benefit in patients with stage IIIB/IIIC or stage IV NSCLC by treating with anti-PD-1/PD-L1 treatment and UV1 vaccination versus anti-PD-1/PD-L1 treatment alone.
This description comes directly from the study's public registry record.
Odd Terje Brustugun, Md, PhD · 32804029 · otr@vestreviken.no
Inger Johanne Zwicky Eide, MD · 32802991 · ingei@vestreviken.no
Always discuss trial participation with your own doctor first.
| Vestre Viken Health Trust | Drammen, Akershus, Norway | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05344209